Baijin Life Science (HKG:1466) reported HK$2.2 million in attributable profit in the fiscal first half, swinging from a loss of HK$6.2 million a year earlier, according to a Hong Kong bourse filing Thursday.

Earnings per share in the half year ended Sept. 30 was HK$0.028, compared with a loss of HK$0.0092 in the prior year.

Revenue dropped to HK$55.1 million from HK$70.9 million last year, figures showed.